−0.474EUR
−30.94 MEUR
50.02 M
About FARON PHARMACEUTICALS OY
Sector
CEO
Markku Tapani Jalkanen
Headquarters
Turku
Website
Employees (FY)
34
Founded
2003
ISIN
FI4000153309
FIGI
BBG00R0D9FX2
Faron Pharmaceuticals Oy is a clinical stage biopharmaceutical company, which engages in the development of drugs to treat acute respiratory distress syndrome. Its main drug candidates include Traumakine and Bex. The company was founded by Juho Markku Jalkanen, Sirpa Tuulikki Jalkanen, Matti Esa Manner, Juha Veikko Peltola, Marko Salmi, Katriina Peltola and Maija-Leena Hollmen, and Markku Tapani Jalkanen in 2003 and is headquartered in Turku, Finland.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of FARON is 1.378 EUR — it has decreased by 0.14% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OMXHEX exchange FARON PHARMACEUTICALS OY stocks are traded under the ticker FARON.
FARON PHARMACEUTICALS OY is going to release the next earnings report on Aug 27, 2024. Keep track of upcoming events with our Earnings Calendar.
FARON stock is 6.07% volatile and has beta coefficient of 0.37. Check out the list of the most volatile stocks — is FARON PHARMACEUTICALS OY there?
One year price forecast for FARON PHARMACEUTICALS OY has a max estimate of 5.000 EUR and a min estimate of 2.000 EUR.
FARON earnings for the last quarter are −0.22 EUR per share, whereas the estimation was −0.30 EUR resulting in a 26.67% surprise. The estimated earnings for the next quarter are −0.20 EUR per share. See more details about FARON PHARMACEUTICALS OY earnings.
FARON PHARMACEUTICALS OY revenue for the last quarter amounts to 0 EUR despite the estimated figure of 0 EUR. In the next quarter revenue is expected to reach 5.00 K EUR.
Yes, you can track FARON PHARMACEUTICALS OY financials in yearly and quarterly reports right on TradingView.
FARON stock has fallen by 7.64% compared to the previous week, the month change is a 37.79% fall, over the last year FARON PHARMACEUTICALS OY has showed a 62.66% decrease.
FARON net income for the last quarter is −17.21 M EUR, while the quarter before that showed −13.73 M EUR of net income which accounts for −25.38% change. Track more FARON PHARMACEUTICALS OY financial stats to get the full picture.
Today FARON PHARMACEUTICALS OY has the market capitalization of 99.37 M, it has decreased by 10.61% over the last week.
No, FARON doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, FARON shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade FARON PHARMACEUTICALS OY stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 20, 2024, the company has 34.00 employees. See our rating of the largest employees — is FARON PHARMACEUTICALS OY on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So FARON PHARMACEUTICALS OY technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating FARON PHARMACEUTICALS OY stock shows the strong sell signal. See more of FARON PHARMACEUTICALS OY technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on FARON PHARMACEUTICALS OY future price: according to them, FARON price has a max estimate of 5.00 EUR and a min estimate of 2.00 EUR. Read a more detailed FARON PHARMACEUTICALS OY forecast: see what analysts think of FARON PHARMACEUTICALS OY and suggest that you do with its stocks.